Pomegra
Merck surged 12.6% on August 19 as a Phase 3 mRNA melanoma vaccine with Moderna cleared key endpoints, marking the first neoantigen therapy to succeed at that stage and easing fears about Keytruda's patent cliff.
- Merck (MRK) closed up 12.6%, near $152, after the INTerpath-001 trial cleared both recurrence-free survival and distant metastasis-free survival endpoints in more than 1,100 patients.
- The result is the first positive Phase 3 readout for any individualized neoantigen therapy in oncology history, a milestone observers described as a "landmark moment" for the field.
- Co-developer Moderna (MRNA) surged roughly 145% on the session, while the Dow Jones Industrial Average advanced a subdued 0.22%, making Merck the runaway outlier among blue-chip names.
Lead
Merck & Co. shares climbed 12.6% on August 19, 2026 - closing near $152 and posting one of the drugmaker's largest single-day advances in at least five years - after the company and co-developer Moderna announced that their personalized mRNA cancer vaccine met its primary and a key secondary endpoint in a Phase 3 melanoma study enrolling more than 1,100 patients. The move made MRK the dominant gainer on the Dow Jones Industrial Average as the broader index crept 0.22% higher to 53,463, ending a three-session losing streak with little of the conviction that drove the pharmaceutical giant's surge.What Did the INTerpath-001 Trial Find?
The Phase 3 INTerpath-001 study demonstrated that intismeran autogene - a patient-specific mRNA neoantigen therapy built from the genetic mutations unique to each individual's tumor - extended both recurrence-free survival and distant metastasis-free survival when combined with Merck's checkpoint inhibitor Keytruda (pembrolizumab). The trial enrolled patients with completely resected stage IIB through IV melanoma whose detectable disease had been surgically removed before treatment began. Both the primary recurrence-free survival endpoint and a prespecified secondary endpoint of distant metastasis-free survival were met at a planned interim data review, with results described as statistically significant and clinically meaningful. The readout marks the first positive Phase 3 result for any individualized neoantigen therapy, validating a scientific approach that has been in clinical development for roughly a decade.
The Phase 3 findings extend a pattern established in the earlier Phase 2b KEYNOTE-942 trial, whose five-year follow-up data presented at the 2026 ASCO Annual Meeting showed the combination reduced the risk of recurrence or death by 49% (hazard ratio 0.51) and cut the risk of distant metastasis or death by 59% (hazard ratio 0.411) relative to Keytruda alone.
Why Does This Matter for Merck's Strategy?
The trial result addresses the central risk hanging over Merck: its dependence on Keytruda, which generated approximately $31.7 billion in 2025 - nearly half the company's total revenue - and faces U.S. patent expiration in December 2028, with biosimilar competition expected to press sales materially through 2029. Intismeran autogene now emerges as the most clearly defined near-term revenue bridge in the post-Keytruda pipeline, with financial analysis projecting roughly $3 billion in potential incremental peak sales from the program. Multiple investment firms raised price targets on MRK in the aftermath, and at least one upgraded the stock.
The strategic logic goes beyond melanoma. Merck and Moderna are studying intismeran in lung, bladder, and kidney cancers, positioning the platform to expand the addressable market well beyond the roughly 100,000 advanced melanoma cases diagnosed globally each year.
How Did Biotech Cancer Stocks React?
Biotech cancer stocks moved broadly higher on the read-across, as the result reinforced the credibility of the mRNA platform in solid tumors beyond infectious disease. Moderna's stock touched an intraday high above $163 before closing near $154, a gain of approximately 145% that recovered a substantial portion of the losses accumulated since the company's pandemic-era peak. The healthcare sector led the S&P 500's sector table for the session; the index gained 0.21% to 7,708, while the Nasdaq Composite added 0.16% to 26,331. The magnitude of Merck's move - more than 50 times the Dow's percentage advance - reflected not just the scientific result but the degree to which the market had previously discounted the company's post-Keytruda prospects.
What Comes Next for Intismeran?
Regulatory submission to the U.S. Food and Drug Administration and parallel filings with major international health authorities represent the likely next step following the Phase 3 data. Both companies said full results would be presented at an upcoming medical conference. The manufacturing process for personalized therapies - each dose is produced individually from a patient's tumor sample - will be a critical operational challenge as the companies prepare for potential commercial scale. Pricing will be another variable, given that individualized production suggests costs well above conventional oncology drugs.
Outlook
August 19 represents a pivotal shift in the investment case for Merck. The company enters the Keytruda patent window now holding a validated Phase 3 asset in a novel oncology category, rather than facing that cliff as an unsolved problem. Regulatory timelines, manufacturing capacity, and payer negotiations will determine how quickly the clinical win converts to revenue. Near term, the result gives MRK its most compelling growth narrative since Keytruda itself redefined cancer treatment over a decade ago.
